Tumor infiltrating CD8+T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma
Authors:
- Mikko MellaMMMikko Mella
- Joonas H KauppilaJKJoonas H Kauppila
- Peeter KarihtalaPKPeeter Karihtala
- Petri LehenkariPLPetri Lehenkari
- Arja Jukkola-VuorinenAJArja Jukkola-Vuorinen
- Ylermi SoiniYSYlermi Soini
- Päivi AuvinenPAPäivi Auvinen
- Markku H VaaralaMVMarkku H Vaarala
- Hanna RonkainenHRHanna Ronkainen
- Saila KauppilaSKSaila Kauppila
- Kirsi-Maria HaapasaariKHKirsi-Maria Haapasaari
- Katri S VuopalaKVKatri S Vuopala
- 8 May 2015
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (6) , e1002726
Abstract
Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival in triple negative breast cancer (TNBC) and renal cell carcinoma (RCC). We hypothesized that this is because TLR9 expression affects tumor immunophenotype. To begin to test this, we compared the number of tumor infiltrating CD8+ T lymphocytes with TLR9 expression in treatment naïve breast cancer (n = 197) and RCC (n = 94) cohorts with known TLR9 expression status. CD8+ T lymphocyte counts were assayed with image analysis after immunohistochemistry (IHC). Tumor TLR9 expression was not correlated with CD8+ T cell counts in breast cancer or RCC. CD8+ T cell counts were significantly associated with tumor proliferation index in TNBC, but not in non-TNBC. CD8+ T cell counts were also significantly associated with tumor grade in non-TNBC, but not in TNBC. In RCC, CD8+ T cell counts were significantly associated with tumor stage. CD8+ T cell counts were significantly associated with prognosis in TNBC and RCC, but the presence of CD8+ T cells in these tumors had opposite effects on disease-specific survival: High CD8+ counts were associated with better prognosis in TNBC and worse prognosis in RCC. Among TNBC patients, those with low tumor TLR9 and low CD8+ T cell counts had the poorest prognosis (log-rank p = 0.0002 vs. high tumor TLR9 and high CD8+ T cell count). In conclusion, pre-treatment tumor TLR9 status is not associated with tumor infiltrating CD8+ T lymphocytes in TNBC or RCC. The combination of TLR9 and CD8+ TIL count might be a novel composite prognostic marker in TNBC.Keywords
This publication has 51 references indexed in Scilit:
- Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillanceby Enhancing Intratumoral Immune Checkpoint ActivityBreast Cancer Research, 2013
- New Insights into the Role of the Immune Microenvironment in Breast CarcinomaJournal of Immunology Research, 2013
- Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancerOncology Letters, 2013
- Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast CancerClinical Cancer Research, 2013
- Intratumoral alterations of dendritic-cell differentiation and CD8+T-cell anergy are immune escape mechanisms of clear cell renal cell carcinomaOncoImmunology, 2012
- Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinomaJournal of Experimental & Clinical Cancer Research, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survivalThe Journal of Pathology, 2011
- JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation inT Cells in Renal Cell Carcinoma PatientsJournal of Biomedicine and Biotechnology, 2010
- Toll‐like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumorsCancer Science, 2010